{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:40:07Z","timestamp":1756312807160,"version":"3.44.0"},"reference-count":25,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Myelomatous pleural effusion (MPE) is an uncommon clinical entity and occurs in less than 1% of all patients with multiple myeloma. MPE indicates a progression of disease, therefore is associated with a poor prognosis and estimated median survival of &lt;3 months. Treatment of MPE is challenging, and the data regarding the role of novel agents lack in the literature. Herein, we report a relapsed IgA myeloma case of a patient presenting with MPE, who was treated with pomalidomide with a very good partial response.<\/jats:p>","DOI":"10.1136\/bcr-2020-235899","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T14:20:11Z","timestamp":1607610011000},"page":"e235899","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Pomalidomide and dexamethasone in myelomatous pleural effusion"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0955-6270","authenticated-orcid":false,"given":"Isin Yagmur","family":"Comba","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Chahin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiffsa","family":"Taj","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Carilli","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Orlando VA Medical Center, Orlando, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"2025082709232526000_13.12.e235899.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2025082709232526000_13.12.e235899.2","first-page":"225","article-title":"Myelomatous pleural effusion: a case series in a single institution and literature review","volume":"31","author":"Cho","year":"2011","journal-title":"Korean J Lab Med"},{"key":"2025082709232526000_13.12.e235899.3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clml.2018.12.003","article-title":"Clinicopathological profile of myelomatous pleural effusion: single-center real-world experience and review of literature","volume":"19","author":"Yanamandra","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082709232526000_13.12.e235899.4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000477793","article-title":"Pleural effusion in multiple myeloma: characteristics and practice patterns","volume":"138","author":"Byun","year":"2017","journal-title":"Acta Haematol"},{"key":"2025082709232526000_13.12.e235899.5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/dc.23894","article-title":"Cytology and clinical features of myelomatous pleural effusion: three case reports and a review of the literature","volume":"46","author":"Chen","year":"2018","journal-title":"Diagn Cytopathol"},{"key":"2025082709232526000_13.12.e235899.6","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/dc.23523","article-title":"Cytomorphology, clinicopathologic, and cytogenetics correlation of myelomatous effusion of serous cavities: a retrospective review","volume":"44","author":"Harbhajanka","year":"2016","journal-title":"Diagn Cytopathol"},{"key":"2025082709232526000_13.12.e235899.7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2169\/internalmedicine.55.4733","article-title":"Pleural effusion in multiple myeloma","volume":"55","author":"Wang","year":"2016","journal-title":"Intern Med"},{"key":"2025082709232526000_13.12.e235899.8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/1759-7714.12220","article-title":"Myelomatous pleural effusion involvement in 23 patients with multiple myeloma: a single-center clinical analysis","volume":"6","author":"Zhong","year":"2015","journal-title":"Thorac Cancer"},{"key":"2025082709232526000_13.12.e235899.9","doi-asserted-by":"publisher","DOI":"10.1378\/chest.64.2.246"},{"key":"2025082709232526000_13.12.e235899.10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.rce.2017.11.001","article-title":"Characteristics of patients with myelomatous pleural effusion. A systematic review","volume":"218","author":"Riveiro","year":"2018","journal-title":"Rev Clin Esp"},{"key":"2025082709232526000_13.12.e235899.11","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3892\/etm.2015.2184","article-title":"Bilateral pleural effusion as an initial manifestation of multiple myeloma: a case report and literature review","volume":"9","author":"Jiang","year":"2015","journal-title":"Exp Ther Med"},{"key":"2025082709232526000_13.12.e235899.12","first-page":"E152","article-title":"Myelomatous pleural effusion as an initial sign of multiple myeloma-a case report and review of literature","volume":"6","author":"Zhang","year":"2014","journal-title":"J Thorac Dis"},{"key":"2025082709232526000_13.12.e235899.13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.622"},{"key":"2025082709232526000_13.12.e235899.14","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500102845"},{"key":"2025082709232526000_13.12.e235899.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538835"},{"key":"2025082709232526000_13.12.e235899.16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/978479","article-title":"Intrapleural bortezomib for the therapy of myelomatous pleural effusion: a case report","volume":"2012","author":"Klanova","year":"2012","journal-title":"Case Reports Immunol"},{"key":"2025082709232526000_13.12.e235899.17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/ccr3.1015","article-title":"Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement","volume":"5","author":"Espa\u00f1ol","year":"2017","journal-title":"Clin Case Rep"},{"key":"2025082709232526000_13.12.e235899.18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.236"},{"key":"2025082709232526000_13.12.e235899.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"2025082709232526000_13.12.e235899.20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.clml.2019.04.003","article-title":"Pomalidomide-Based regimens for treatment of relapsed and relapsed\/refractory multiple myeloma: systematic review and meta-analysis of phase 2 and 3 clinical trials","volume":"19","author":"Mushtaq","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025082709232526000_13.12.e235899.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0711-6"},{"key":"2025082709232526000_13.12.e235899.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"2025082709232526000_13.12.e235899.23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.13046","article-title":"Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis","volume":"100","author":"Pick","year":"2018","journal-title":"Eur J Haematol"},{"key":"2025082709232526000_13.12.e235899.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"2025082709232526000_13.12.e235899.25","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-235899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:23:33Z","timestamp":1756311813000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-235899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,10]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bcr-2020-235899"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-235899","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}